“The Metformin Active Surveillance Trial (MAST) Study”
This study aims to see if metformin can delay the time to progression in men with low risk prostate cancer when compared to a placebo.
Drug - Metformin
One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
Drug - Placebo
One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study